Cancer – AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Condition or Therapy:
B Acute Lymphoblastic Leukemia
Cancer and Blood Disorders
Study Number: AALL1631
What is the goal of this study?
This study looks at how well imatinib mesylate works in combination with chemotherapy to treat patients with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 2 to 21 years old, and
- have newly diagnosed denovo ALL that have previously started induction therapy.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.